Your cart is empty.
Männedorf, Switzerland, September 22, 2010 – Pfizer has chosen Tecan’s Freedom EVO® to revolutionize DNA extraction workflows at its BioBank facility in Connecticut, USA, dramatically increasing throughput while reducing waste generation and costs. Bob Corr, Principle Scientist at the DNA and BioFluids Center of Emphasis, explained: “The quantity of DNA required for downstream processing had decreased significantly, from approximately 250 μg to 6 μg, since the inception of the first generation extraction process. This reduction in volume has allowed us to fully automate sample handling for both DNA extraction and long term whole blood storage using the Freedom EVO platform, and our entire laboratory workflow has been updated to reflect these changes in practice.”
Bob concluded: “Introduction of the second generation extraction protocol has made a huge difference to our overall throughput. Working with lower sample volumes in 96-well microplate format means we now process 96 samples in around 2 hours, compared to 11.5 hours using the old protocol, significantly increasing throughput and reducing both the cost per sample and the volume of biohazardous waste. We are now working with Tecan to implement parallel processing of three microplates using the dynamic scheduling capabilities of Freedom EVOware® Plus, which will increase our capacity to almost 1000 samples a day, more than 10 times the throughput of our old method.”
To find out more on Tecan’s Freedom EVO liquid handling platforms, visit www.tecan.com/freedomevo
For more information please contact
Tecan Trading AG
Tel +41 (0)44 922 81 11
Fax +41 (0)44 922 81 12
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of instruments and automated workflow solutions for laboratories in the life sciences sector. As an original equipment manufacturer, Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2009, Tecan generated sales of CHF 392 million (USD 361.2 million; EUR 259.6 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN CH0012100191).